 Home > Active Ingredient News > Endocrine System > Hepatology: The influence of hypoglycemic drugs and blood sugar control on the risk of liver cancer in patients with non-alcoholic fatty liver

Hepatology: The influence of hypoglycemic drugs and blood sugar control on the risk of liver cancer in patients with non-alcoholic fatty liver

 Last Update: 2021-12-03
 Source: Internet
 Author: User

Tags

blood typing slide

heparin blood tube

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Non-alcoholic fatty liver disease (NAFLD) patients with type 2 diabetes (DM) are at high risk of developing hepatocellular carcinoma (HCC)

diabetes

In this study we were collected between January 2004 to December 2008 at 31 Veterans Administration patients diagnosed out of 130 facilities Bureau of diabetes in non-alcoholic fatty liver disease retrospective cohort

Administer Metformin

The influence of various risk factors on the risk of liver cancer

A total of 85,963 non-alcoholic fatty liver disease patients with diabetes mellitus were identified

Compared with no treatment, metformin can reduce the risk of hepatocellular carcinoma by 20% compared with no treatment, metformin can reduce by 20% the risk of hepatocellular carcinoma hepatocellular carcinoma risk does not affect insulin had no effect on insulin risk of hepatocellular carcinoma insulin other oral drugs when used in combination can increase the risk of hepatocellular carcinoma 1.

The use of metformin is associated with a reduced risk of hepatocellular carcinoma, while combined hypoglycemic therapy is associated with an increased risk of hepatocellular carcinoma

Original source:

Kramer Jennifer R,Natarajan Yamini,Dai Jianliang et al.

Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with non-alcoholic fLeave a

message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Cetrorelix 99% White powder High Quality Cetrorelix

CAS No.: 120287-85-6

Pharmacy Grade

$2-2.3/G FOB

β-Estradiol 17-valerate 98% Powder 979-32-8 Estradiol Valerate

CAS No.: 979-32-8

Pharmacy Grade

$2-2.2/G FOB

API Potassium iodide 99% Powder TGY2022101201 with good price Ouda

CAS No.: 7681-11-0

Pharmacy Grade

$2.1-2.7/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.